drugset / Trial / NCT05037149
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2024-03-30
- Completion
- 2024-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STP707 | Small interfering RNA (siRNA) | 3 mg | Intravenous |
| Subject | STP707 | Small interfering RNA (siRNA) | 6 mg | Intravenous |
| Subject | STP707 | Small interfering RNA (siRNA) | 12 mg | Intravenous |
| Subject | STP707 | Small interfering RNA (siRNA) | 24 mg | Intravenous |
| Subject | STP707 | Small interfering RNA (siRNA) | 36 mg | Intravenous |
| Subject | STP707 | Small interfering RNA (siRNA) | 48 mg | Intravenous |